Pathophysiological basis of pharmacotherapy in the hepatorenal syndrome

Scandinavian Journal of Gastroenterology

Volumn 40, Issue 5, 2005, Pages 491-500

  Møller, Søren ^a,b   Bendtsen, Flemming ^a   Henriksen, Jens H ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

Author keywords

Arterial hypotension; Cirrhosis; Portal hypertension; Renin angiotensin aldosterone system; Sympathetic nervous system

Indexed keywords

1 [3 (2 PHENYLPYRAZOLO[1,5 A]PYRIDIN 3 YL)ACRYLOYL]PIPERIDINE 2 ACETIC ACID; ADENOSINE RECEPTOR BLOCKING AGENT; ANGIOTENSIN ANTAGONIST; ARGIPRESSIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; ENDOTHELIN RECEPTOR ANTAGONIST; KAPPA OPIATE RECEPTOR ANTAGONIST; LIXIVAPTAN; LOSARTAN; PLASMA SUBSTITUTE; TERLIPRESSIN; THEOPHYLLINE; VASOCONSTRICTOR AGENT; VASOPRESSIN RECEPTOR ANTAGONIST;

ADRENERGIC SYSTEM; HEPATORENAL SYNDROME; HUMAN; HYPOTENSION; HYPOVOLEMIA; KIDNEY FUNCTION; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER FUNCTION; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; PORTOSYSTEMIC ANASTOMOSIS; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; VASOCONSTRICTION;

ADENOSINE; ADRENERGIC BETA-ANTAGONISTS; ENDOTHELINS; HEPATORENAL SYNDROME; HUMANS; HYPERTENSION, PORTAL; HYPOTENSION; HYPOVOLEMIA; KIDNEY; LIVER; PORTASYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC; RENAL VEINS; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS;

EID: 18744381028     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365520510012064     Document Type: Review

References (112)

1. Ring-Larsen H. Renal blood flow in cirrhosis: relation to systemic and portal haemodynamics and liver function. Scand J Clin Lab Invest 1977;37:635-42.
2. Henriksen JH. Cirrhosis: ascites and hepatorenal syndrome. Recent advances in pathogenesis. J Hepatol 1995;23:25-30.
3. Bernardi M, Blendis L, Burroughs AK, Laffi G, Rodes J, Gentilini P. Hepatorenal syndrome and ascites: questions and answers. Liver 1999;19:15-74.
4. Dagher L, Moore K. The hepatorenal syndrome. Gut 2001;49:729-37.
5. Gentilini P, Vizzutti F, Gentilini A, Zipoli M, Foschi M, Romanelli RG. Update on ascites and hepatorenal syndrome. Dig Liver Dis 2002;34:592-605.
6. Gines P, Cardenas A, Arroyo V, Rodes J. Management of cirrhosis and ascites. N Engl J Med 2004;350:1646-54.
7. Gines P, Guevara M, Arroyo V, Rodes J. Hepatorenal syndrome. Lancet 2003;362:1819-27.
8. Arroyo V, Gines P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 1996;23:164-76.
9. Epstein M. Renal sodium handling in liver disease. In: Epstein M, editor. The kidney in ILiver disease, 4th ed. Philadelphia: Hanley and Belfus; 1996. pp 1-31.
10. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodés J. Peripheral artery vasodilatation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988;5:1151-7.
11. Møller S, Henriksen JH. Circulatory abnormalities in cirrhosis with focus on neurohumoral aspects. Semin Nephrol 1997;17:505-19.
12. Wiest R, Groszmann RJ. The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. Hepatology 2002;35:478-91.
13. La Villa G, Barletta G, Pantaleo P, Del Bene R, Vizzutti F, Vecchiarino S, et al. Hemodynamic, renal, and endocrine effects of acute inhibition of nitric oxide synthase in compensated cirrhosis. Hepatology 2001;34:19-27.
14. Gerbes AL, Gülberg V, Waggershauser T, Holl J, Reiser M. Renal effects of transjugular intrahepatic portosystemic shunt in cirrhosis: comparison of patients with ascites, with refractory ascites, or without ascites. Hepatology 1998;28: 683-8.
15. Moreau R, Asselah T, Condat B, de Kerguenec C, Pessione F, Bernard B, et al. Comparison of the effect of terlipressin and albumin on arterial blood volume in patients with cirrhosis and tense ascites treated by paracentesis: a randomised pilot study. Gut 2002;50:90-4.
16. Gines P, Uriz J, Calahorra B, Garcia-Tsao G, Kamath PS, del Arbol LR, et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology 2002;123:1839-47.
17. Laffi G, La Villa G, Gentilini P. Pathogenesis and management of the hepatorenal syndrome. Sem Liver Dis 1994; 14:71-81.
18. Arroyo V, Guevara M, Gines P. Hepatorenal syndrome in cirrhosis: Pathogenesis and treatment. Gastroenterology 2002;122:1658-76.
19. Cassinello C, Moreno E, Gozalo A, Ortuno B, Cuenca B, Solis-Herruzo JA. Effects of orthotopic liver transplantation on vasoactive systems and renal function in patients with advanced liver cirrhosis. Dig Dis Sci 2003;48:179-86.
20. Arroyo V, Colmenero J. Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. J Hepatol 2003;38(Suppl 1):S69-89.
21. Kostreva DR, Pontus SP. Hepatic vein, hepatic parenchymal, and inferior vena caval mechanoreceptors with phrenic afferents. Am J Physiol 1993;28:G15-20.
22. Levy M, Wexler MJ. Hepatic denervation alters first-phase urinary sodium excretion in dogs with cirrhosis. Am J Physiol 1987;253:F664-F71.
23. Jalan R, Forrest EH, Redhead DN, Dillon JF, Hayes PC. Reduction in renal blood flow following acute increase in the portal pressure: evidence for the existence of a hepatorenal reflex in man? Gut 1997;40:664-70.
24. Kapoor D, Redhead DN, Hayes PC, Webb DJ, Jalan R. Systemic and regional changes in plasma endothelin following transient increase in portal pressure. Liver Transpl 2003;9:32-9.
25. Ming Z, Smyth DD, Lautt WW. Decreases in portal flow trigger a hepatorenal reflex to inhibit renal sodium and water excretion in rats: role of adenosine. Hepatology 2002;35:167-75.
26. Møller S, Henriksen JH. The systemic circulation in cirrhosis. In: Arroyo V, Gines P, Rodes J, Schrier RW, editors. Ascites and renal dysfunction in liver disease. Malden: Blackwell; 1999. pp 307-29.
27. Groszmann RJ. Vasodilatation and hyperdynamic circulatory state in chronic liver disease. In: Bosch J, Groszmann RJ, editors. Portal hypertension. Pathophysiology and treatment, 1st ed. Oxford: Blackwell; 1994. pp 17-26.
28. Møller S, Henriksen JH. Neurohumoral fluid regulation in chronic liver disease. Scand J Clin Lab Invest 1998;58: 361-72.
29. Henriksen JH, Ring-Larsen H. Hepatorenal disorders:Role of the sympathetic nervous system. Sem Liver Dis 1994; 14:35-43.
30. Jalan R, Mookerjee RP, Hayes PC, Redhead DN, Moore K, Williams R. Evidence for altered renal blood flow autoreulation in cirrhosis. Hepatology 2003;38:416A-7A.
31. Dagher L, Patch D, Marley R, Moore K, Burroughs A. Pharmacological treatment of the hepatorenal syndrome in cirrhotic patients [review], [in process citation]. Aliment Pharmacol Ther 2000;14:515-21.
32. Llach J, Ginés P, Arroyo V, Rimola A, Titó L, Badalamenti S, et al. Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology 1988;94:482-7.
33. Thiesson HC, Skøtt O, Jespersen B, Schaffalitzky de Muckadell OB. Nitric oxide synthase inhibition does not improve renal function in cirrhotic patients with ascites. Am J Gastroenterol 2003;98:180-6.
34. Ma Z, Lee SS. Cirrhotic cardiomyopathy: getting to the heart of the matter. Hepatology 1996;24:451-9.
35. Ruiz-Del-Arbol L, Urman J, Fernandez J, Gonzalez M, Navasa M, Monescillo A, et al. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 2003;38:1210-8.
36. La Villa G, Salmeron JM, Arroyo V, Bosch J, Gines P, Garcia-Pagan JC, et al. Mineralocorticoid escape in patients with compensated cirrhosis and portal hypertension. Gastroenterology 1992;102:2114-9.
37. Bernardi M, Trevisani F, Gasbarrini A, Gasbarrini G. Hepatorenal disorders. Role of the renin-angiotensin-aldosterone system. Sem Liver Dis 1994;14:23-34.
38. Møller S, Bendtsen F, Henriksen JH. Vasoactive substances in the circulatory dysfunction of cirrhosis. Scand J Clin Lab Invest 2001;61:421-9.
39. Dibona GF, Kopp UC. Neural control of renal function. Physiol Rev 1997;77:75-197.
40. Gentilini P, Romanelli RG, La Villa G, Maggiore Q, Pesciullesi E, Cappelli G, et al. Effects of low-dose captopril on renal hemodynamics and function in patients with cirrhosis of the liver. Gastroenterology 1993;104:588-94.
41. Gonzalez-Abraldes J, Albillos A, Banares R, del Arbol LR, Moitinho E, Rodriguez C, et al. Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis. Gastroenterology 2001;121:382-8.
42. Wong F, Blei AT, Blendis LM, Thuluvath PJ. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology 2003; 37:182-91.
43. Gerbes AL, Gülberg V, Gines P, Decaux G, Gross P, Gandjini H, et al. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology 2003;124: 933-9.
44. Navasa M, Feu F, Garcia-Pagan JC, Jimenez W, Llach J, Rimola A, et al. Hemodynamic and humoral changes after liver transplantation in patients with cirrhosis. Hepatology 1993;17:355-60.
45. Guevara M, Gines P, Bandi JC, Gilabert R, Sort P, Jimenez W, et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology 1998;28:416-22.
46. Brensing KA, Textor J, Perz J, Schiedermaier P, Raab P, Strunk H, et al. Long-term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut 2000;47:288-95.
47. Colombato LA, Spahr L, Martinet JP, Dufresne MP, Lafortune M, Fenyves D, et al. Haemodynamic adaptation two months after transjugular intrahepatic portosystemic shunt (TIPS) in cirrhotic patients. Gut 1996;39:600-4.
48. Merli M, Valeriano V, Funaro S, Attili AF, Masini A, Efrati C, et al. Modifications of cardiac function in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt (TIPS). Am J Gastroenterol 2002;97:142-8.
49. Salerno F, Cazzaniga M, Pagnozzi G, Cirello I, Nicolini A, Meregaglia D, et al. Humoral and cardiac effects of TIPS in cirrhotic patients with different "effective" blood volume. Hepatology 2003;38:1370-7.
50. Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 2004;40:55-64.
51. Henriksen JH, Ring-Larsen H. Renal effects of drugs used in the treatment of portal hypertension. Hepatology 1993; 18:688-95.
52. Henriksen JH, Møller S, Ring-Larsen H, Christensen NJ. The sympathetic nervous system in liver disease. J Hepatol 1998;29:328-41.
53. Stanley AJ, Therapondos G, Helmy A, Hayes PC. Acute and chronic haemodynamic and renal effects of carvedilol in patients with cirrhosis. J Hepatol 1999;30:479-84.
54. Mitzner SR, Stange J, Klammt S, Risler T, Erley CM, Bader BD, et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl 2000;6:277-86.
55. Moreau R, Lebrec D. Acute renal failure in patients with cirrhosis: perspectives in the age of MELD. Hepatology 2003;37:233-43.
56. Khuroo MS, Khuroo MS, Farahat KL. Molecular adsorbent recirculating system for acute and acute-on-chronic liver failure: a meta-analysis. Liver Transpl 2004;10:1099-6.
57. Hadengue A, Gadano A, Moreau R, Giostra E, Durand F, Valla D, et al. Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. J Hepatol 1998;29:565-70.
58. Uriz J, Gines P, Cardenas A, Sort P, Jimenez W, Salmeron JM, et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol 2000; 33:43-8.
59. Møller S, Hansen EF, Becker U, Brinch K, Henriksen JH, Bendtsen F. Central and systemic haemodynamic effects of terlipressin in portal hypertensive patients. Liver 2000;20: 51-9.
60. Mulkay JP, Louis H, Donckier V, Bourgeois N, Adler M, Deviere J, et al. Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study. Acta Gastroenterol Belg 2001;64:15-9.
61. Ortega R, Gines P, Uriz J, Cardenas A, Calahorra B, De Las HD, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 2002; 36:941-8.
62. Moreau R, Durand F, Poynard T, Duhamel C, Cervoni JP, Ichai P, et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 2002;122:923-30.
63. Guevara M, Gines P, Fernandez-Esparrach G, Sort P, Salmeron JM, Jimenez W, et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology 1998;27:35-41.
64. Ottesen LH, Aagaard NK, Kiszka-Kanowitz M, Rehling M, Henriksen JH, Pedersen EB, et al. Effects of a long-acting formulation of octreotide on renal function and renal sodium handling in cirrhotic patients with portal hypertension: a randomized, double-blind, controlled trial. Hepatology 2001;34:471-7.
65. Duvoux C, Zanditenas D, Hezode C, Chauvat A, Monin JL, Roudot-Thoraval F, et al. Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study. Hepatology 2002;36:374-80.
66. Pomier-Layrargues G, Paquin SC, Hassoun Z, Lafortune M, Tran A. Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study. Hepatology 2003,38:238-43.
67. Angeli P, Volpin R, Gerunda G, Craighero R, Roner P, Merenda R, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999;29:1690-7.
68. Dillon JF, Nolan J, Thomas H, Williams BC, Neilson JMM, Bouchier IAD, et al. The correction of autonomic dysfunction in cirrhosis by captopril. J Hepatol 1997;26: 331-5.
69. Rangari M, Sinha S, Kapoor D, Mohan JC, Sarin SK. Prevalence of autonomic dysfunction in cirrhotic and noncirrhotic portal hypertension. Am J Gastroenterol 2002;97:707-13.
70. Hendrickse MT, Triger DR. Vagal dysfunction and impaired urinary sodium and water excretion in cirrhosis. Am J Gastroenterol 1994;89:750-7.
71. Laffi G, Barletta G, Lavilla G, Delbene R, Riccardi D, Ticali P, et al. Altered cardiovascular responsiveness to active tilting in nonalcoholic cirrhosis. Gastroenterology 1997;113:891-8.
72. Villa GL, Barletta G, Romanelli RG, Laffi G, Del Bene R, Vizzutti F, et al. Cardiovascular effects of canrenone in patients with preascitic cirrhosis. Hepatology 2002;35: 1441-8.
73. Moreau R, Hadengue A, Soupison T, Mechin G, Assous M, Roche-Sicot J, et al. Abnormal presser response to vasopressin in patients with cirrhosis: evidence for impaired buffering mechanisms. Hepatology 1990;12:7-12.
74. Ryan J, Sudhir K, Jennings G, Esler M, Dudley F. Impaired reactivity of the peripheral vasculature to pressor agents in alcoholic cirrhosis. Gastroenterology 1993;105:1167-72.
75. Møller S, Henriksen JH. Cirrhotic cardiomyopathy: a pathophysiological review of circulatory dysfunction in liver disease. Heart 2002;87:9-15.
76. Møller S, Søndergaard L, Møgelvang J, Henriksen O, Henriksen JH. Decreased right heart blood volume determined by magnetic resonance imaging: evidence of central underfilling in cirrhosis. Hepatology 1995;22:472-8.
77. Bernardi M, Fornale L, Dimarco C, Trevisani F, Baraldini M, Gasbarrini A, et al. Hyperdynamic circulation of advanced cirrhosis: a reappraisal based on posture-induced changes in hemodynamics. J Hepatol 1995;22:309-18.
78. Luca A, Feu F, Garcia-Pagan JC, Jiménez W, Arroyo V, Bosch J, et al. Favorable effects of total paracentesis on splanchnic hemodynamics in cirrhotic patients with tense ascites. Hepatology 1994;20:30-3.
79. Ruiz del Arbol L, Monescillo A, Jimenez W, Garcia-Plaza A, Arroyo V, Rodes J. Paracentesis-induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis. Gastroenterology 1997;113:579-86.
80. Cabrera J, Falcon L, Gorriz E, Pardo MD, Granados R, Quinones A, et al. Abdominal decompression plays a major role in early postparacentesis haemodynamic changes in cirrhotic patients with tense ascites. Gut 2001;48:384-9.
81. Sola-Vera J, Minana J, Ricart E, Planella M, Gonzalez B, Torras X, et al. Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites. Hepatology 2003;37:1147-53.
82. Arroyo V, Jimenez W. Clinical need for antidiuretic hormone antagonists in cirrhosis. Hepatology 2003;37: 13-5.
83. Moore K, Wendon J, Frazer M, Karani J, Williams R, Badr K. Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome. N Engl J Med 1992;327:1774-8.
84. Anand R, Harry D, Holt S, Milner P, Dashwood M, Goodier D, et al. Endothelin is an important determinant of renal function in a rat model of acute liver and renal failure. Gut 2002;50:111-7.
85. Fevery J, Van Cutsem E, Nevens F, Van Steenbergen W, Verberckmoes R, De Groote J. Reversal of hepatorenal syndrome in four patients by peroral misoprostol (prostaglandin E1 analogue) and albumin administration. J Hepatol 1990;11:153-8.
86. Moore K, Ward PS, Taylor GW, Williams R. Systemic and renal production of thromboxane A2 and prostacyclin in decompensated liver disease and hepatorenal syndrome. Gastroenterology 1991;100:1069-77.
87. Epstein M, Schneider N, Befeler B. Relationship of systemic and intrarenal hemodynamics in cirrhosis. J Lab Clin Med 1977;89:1175-87.
88. Epstein M. Hepatorenal syndrome: emerging perspectives of pathophysiology and therapy. J Am Soc Nephrol 1994;4: 1735-53.
89. Schneider AW, Kalk JF, Klein CP. Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis. Hepatology 1999;29:334-9.
90. Garcia-Tsao G. Angiotensin II receptor antagonists in the pharmacological therapy of portal hypertension: a caution. Gastroenterology 1999;117:740-2.
91. Epstein M, Weitzman RE, Preston S, Denunzio AG. Relationship between plasma arginine vasopressin and renal water handling in decompensated cirrhosis. Min Electr Metab 1984;10:155-65.
92. Guyader D, Patat A, Ellis-Grosse EJ, Orczyk GP. Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites. Hepatology 2002;36:1197-205.
93. FernandezLlama P, Turner R, Dibona G, Knepper MA. Renal expression of aquaporins in liver cirrhosis induced by chronic common bile duct ligation in rats. J Am Soc Nephrol 1999;10:1950-7.
94. Claria J, Jimenez W, Arroyo V, La Villa G, Lopez C, Asbert M, et al. Effect of V-1-vasopressin receptor blockade on arterial pressure in conscious rats with cirrhosis and ascites. Gastroenterology 1991;100:494-501.
95. Morales J, Moitinho E, Abraldes JG, Fernandez M, Bosch J. Effects of the Via vasopressin agonist F-180 on portal hypertension-related bleeding in portal hypertensive rats. Hepatology 2003;38:1378-83.
96. Gerbes AL, Møller S, Gülberg V, Henriksen JH. Endothelin-1 and -3 plasma concentrations in patients with cirrhosis: role of splanchnic and renal passage and liver function. Hepatology 1995;21:735-9.
97. Møller S, Henriksen JH. Endothelins in chronic liver disease. Scand J Clin Lab Invest 1996;56:481-90.
98. Bernardi M, Gülberg V, Colantoni A, Trevisani F, Gasbarrini A, Gerbes AL. Plasma endothelin-1 and -3 in cirrhosis: relationship with systemic hemodynamics, renal function and neurohumoral systems. J Hepatol 1996;24: 161-8.
99. Moore K. Endothelin and vascular function in liver disease. Gut 2004;53:159-61.
100. Soper CP, Latif AB, Bending MR. Amelioration of hepatorenal syndrome with selective endothelin-A antagonist. Lancet 1996;347:1842-3.
101. Llach J, Gines P, Arroyo V, Salmeron JM, Gines A, Jimenez W, et al. Effect of dipyridamole on kidney function in cirrhosis. Hepatology 1993;17:59-64.
102. Milani L, Merkel C, Gatta A. Renal effects of aminophylline in hepatic cirrhosis. Eur J Clin Pharmacol 1983;24: 757-60.
103. Forrest EH, Bouchier IAD, Hayes PC. Acute effect of low dose theophylline on the circulatory disturbances of cirrhosis. Gut 1997;40:139-44.
104. Stanley AJ, Forrest EH, Dabos K, Bouchier IAD, Hayes PC. Natriuretic effect of an adenosine-1 receptor antagonist in cirrhotic patients with ascites. Gastroenterology 1998;115:406-11.
105. Angeli P, Jimenez W, Arroyo V, Mackenzie HS, Zhang PL, Claria J, et al. Renal effects of natriuretic peptide receptor blockade in cirrhotic rats with ascites. Hepatology 1994; 20:948-54.
106. Ros J, Claria J, Jimenez W, Boschmarce M, Angeli P, Arroyo V, et al. Role of nitric oxide and prostacyclin in the control of renal perfusion in experimental cirrhosis. Hepatology 1995;22:915-20.
107. Zipser RD, Radvan GM, Kronborg IJ, Duke R, Little T. Urinary thromboxane B2 and prostaglandinE2 in the hepatorenal syndrome: evidence for increased vasoconstrictor and decreased vasodilator factors. Gastroenterology 1983;84:697-703.
108. Rimola A, Gines P, Arroyo V. Urinary excretion of 6-keto-PGF-I-alpha, thromboxane B-2 and prostaglandin E-2 in cirrhosis with ascites: relationship to functional renal failure (hepatorenal syndrome). J Hepatol 1986;3:111-7.
109. Gines A, Salmeron JM, Gines P, Arroyo V, Jimenez W, Rivera F, et al. Oral misoprostol or intravenous prostaglandin E2 does not improve renal function in patients with cirrhosis and ascites with hyponatremia or renal failure. J Hepatol 1993;17:220-6.
110. Rockey DC, Chung JJ. Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: endothelial dysfunction in portal hypertension. Gastroenterology 1998;114: 344-51.
111. McNaughton L, Puttagunta L, Martinez-Cuesta MA, Kneteman N, Mayers I, Moqbel R, et al. Distribution of nitric oxide synthase in normal and cirrhotic human liver. Proc Natl Acad Sci USA 2002;99:17161-6.
112. Farzaneh-Far R, Moore K. Nitric oxide and the liver. Liver 2001;21:161-74.